Ocugen, Inc., a biotechnology company focused on gene therapies for blindness diseases, announced updates to its Retina Scientific Advisory Board and Executive Leadership Team. These changes are ...
EyeBio doubles the size of its original Series A raise with an additional $65 million, with new investors Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC joining the round to support ...
Scientists led by Botond Roska at the Institute of Molecular and Clinical Ophthalmology Basel (IOB) and collaborators have ...
AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs) focused on large gene delivery via its two proprietary Adeno-Associated ...
Until now, it has been difficult to maintain retinal ganglion cells deep inside organoids over extended periods. The supply of nutrients and oxygen in the densely packed tissues is limited, leading to ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Therini Bio, Inc., a biotech company aimed at developing fibrin-targeted therapies to treat inflammatory neurodegenerative and retinal diseases, today ...
The condition of the eye’s retina, and in particular the measure of retinal thickness (influenced by factors such as the amount of vascularization, atrophy, ischemic damage, and the presence or ...
LAS VEGAS, June 4, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company ...
Scientists have taken a major step toward protecting the very cells that make sharp, colorful vision possible. By testing ...
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced financial results for the fourth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results